Pieris Pharma (PIRS) Reports In-Line Q2 Loss
Tweet
Share
E-mailGet Alerts PIRS Hot Sheet
Join SI Premium – FREE
Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $300 thousand.
For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
